Announced in June, the cash deal reflects continued consolidation in the CDMO space.

In June, Albany Molecular Research (AMRI) announced the company was to be private and would be acquired for approximately $922 million in cash. AMRI has since announced the completion of the acquisition, a deal brought by affiliates of the private equity firm GTCR and global alternative asset manager the Carlyle group.

AMRI President and CEO, William S. Marth, explained: “This transaction is a strong endorsement of our strategy. Given their deep healthcare industry expertise and financial resources, Carlyle and GTCR are highly attractive partners for us and offer a compelling opportunity to accelerate our growth and enhance delivery of world-class solutions to our customers.” AMRI said Marth will continue to lead the company.

Several financial and legal advisors participated in the structuring and execution of the deal including Credit Suisse and Proctor LLP. Equity capital for Carlyle’s investment came from Carlyle Partners Fund VI and for GTCR, the GTCR Fund XI. Kirkland & Ellis served as GTCR’s legal advisor and Latham & Watkins advised Carlyle Group. Barclays, Bourne Partners and Morgan Stanley also acted as advisors in connection with the transaction. RBC Capital Markets, Morgan Stanley, Goldman Sachs Bank USA, Jeffries Finance LLC, Mizuho Bank ltd. and Risk Advisors were additionally involved in the guidance and execution of the transaction.